HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fulvia Farabegoli Selected Research

6-OH-11-O-hydroxyphenanthrene

8/2018Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro.
6/2017EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces breast cancer cell invasion.
1/2014A RXR ligand 6-OH-11-O-hydroxyphenanthrene with antitumour properties enhances (-)-epigallocatechin-3-gallate activity in three human breast carcinoma cell lines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Fulvia Farabegoli Research Topics

Disease

10Neoplasms (Cancer)
01/2022 - 10/2003
6Breast Neoplasms (Breast Cancer)
06/2017 - 10/2003
2Colonic Neoplasms (Colon Cancer)
02/2021 - 06/2013
2Pancreatic Neoplasms (Pancreatic Cancer)
12/2020 - 03/2019
2Neoplasm Metastasis (Metastasis)
06/2017 - 04/2011
1Necrosis
02/2021
1Adenocarcinoma
02/2021
1Colorectal Neoplasms (Colorectal Cancer)
02/2021
1Ovarian Neoplasms (Ovarian Cancer)
03/2019
1Neuroblastoma
08/2018
1Carcinoma (Carcinomatosis)
01/2016
1Cholangiocarcinoma
01/2016
1Gastrointestinal Neoplasms (Gastrointestinal Cancer)
01/2016

Drug/Important Bio-Agent (IBA)

5TeaIBA
08/2018 - 01/2007
5Catechin (Z 7300)IBA
08/2018 - 01/2007
4epigallocatechin gallate (epigallocatechin-3-gallate)IBA
01/2022 - 01/2016
36-OH-11-O-hydroxyphenanthreneIBA
08/2018 - 01/2014
2olaparibIBA
12/2020 - 03/2019
2DNA (Deoxyribonucleic Acid)IBA
04/2020 - 10/2003
2ErbB Receptors (EGF Receptor)IBA
06/2017 - 04/2011
2Retinoid X Receptors (Retinoid X Receptor)IBA
06/2017 - 01/2016
2Metalloproteases (Metalloproteinases)IBA
01/2016 - 04/2011
2LigandsIBA
01/2016 - 01/2014
2Basigin (Extracellular Matrix Metalloproteinase Inducer (EMMPRIN))IBA
01/2016 - 04/2011
2TamoxifenFDA LinkGeneric
04/2011 - 01/2007
2Steroid Receptors (Steroid Receptor)IBA
01/2007 - 04/2004
1LipidsIBA
01/2022
1cinnamaldehyde (cinnamic aldehyde)FDA Link
02/2021
1EugenolIBA
02/2021
1Volatile Oils (Essential Oils)IBA
02/2021
1Proteins (Proteins, Gene)FDA Link
04/2020
1MethyltransferasesIBA
04/2020
1CateninsIBA
04/2020
1RetinoidsIBA
08/2018
1Pharmaceutical PreparationsIBA
01/2016
1Reactive Oxygen Species (Oxygen Radicals)IBA
06/2013
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
06/2013
1IsothiocyanatesIBA
06/2013
1vitexin-2-O-xylosideIBA
06/2013
14-(methylthio)-3-butenyl isothiocyanateIBA
06/2013
1Caspase 9IBA
06/2013
1gallocatechol (epigallocatechin)IBA
04/2011
1Matrix Metalloproteinases (MMPs)IBA
04/2011
1Glycoproteins (Glycoprotein)IBA
04/2011
1Fulvestrant (Faslodex)FDA Link
01/2007
1Estrogen Receptor alphaIBA
01/2007
1Complement System Proteins (Complement)IBA
01/2007
1Estrogens (Estrogen)FDA Link
04/2004
1Cyclin D1IBA
04/2004
1Progesterone Receptors (Progesterone Receptor)IBA
04/2004
1Cyclin AIBA
04/2004
1Arginine (L-Arginine)FDA Link
10/2003
1Proline (L-Proline)FDA Link
10/2003
1Codon (Codons)IBA
10/2003

Therapy/Procedure

5Therapeutics
01/2022 - 10/2003
3Chemoprevention
01/2022 - 06/2013
1Aftercare (After-Treatment)
01/2016